Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated May 2, 2017 (9 years ago)

Famotidine for Oral Suspension USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Famotidine for Oral Suspension USP, 40 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Goa 403 722 INDIA, NDC 68180-150-01

Affected NDC 68180-0150-01

Compare with the code on your package — it is the most precise check available.

Drug: Famotidine Category: Heartburn & Stomach Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Famotidine
NDC 68180-0150
40 mg/5mL Powder, for Suspension
Oral
Lupin Pharmaceuticals, Inc. Rx
Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
68180-150-01
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1127-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Famotidine recalls

See all
Class I · High risk

Famotidine Injection

Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.

Ongoing Microbial contamination Fresenius Kabi USA, LLC NDC 63323-739-11 D-0182-2026
Class II · Moderate risk

Famotidine Tablets

Labeling: Label Error on Declared Strength: some cartons labeled and containing 20 mg may have an external label placed on the side of the carton indicating strength as 10 mg.

Terminated Labeling / mix-up Glenmark Therapeutics, Inc. NDC 72657-113-20 D-0939-2023
Class II · Moderate risk

Famotidine Tablets USP 40mg

Presence of foreign tablets/capsules: Famotidine 20mg and ibuprofen 400mg tablets were found in a lot of famotidine 40mg.

Terminated Particulate / foreign matter Aurobindo Pharma USA Inc. NDC 65862-860-99 D-0290-2021

Other recalls by Lupin Pharmaceuticals Inc.

All 2017 recalls